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During the last twenty years, a huge progress has been achieved in the treatment of liver
cancer and recent strategies include interventional radiology, chemotherapy regimens and
surgery. Meanwhile, Stereotactic Body Radiation Therapy (SRBT) has developed in the treat-
ment  of all organs with millimetre accuracy, very few side effects and a high control rate.
So, SRBT has become a therapeutic weapon in his own right in liver tumour treatment.
Many publications have reported encouraging results in colorectal liver metastasis, hepa-
tocellular carcinoma on cirrhosis and peripheric cholangiocarcinoma. It is important that





therapeutic indications and initiate treatments quickly.
© 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.1.  Background
Until now, surgery has played a central role in the treat-
ment of liver cancer. Even though for several decades, surgical
resection was the only potentially curative option, since 15
years, the therapeutic arsenal has significantly increased. Sys-
temic and local chemotherapy, techniques of thermo ablation
and, more  recently, stereotactic radiotherapy, have shown
encouraging results and are more  and more  used currently
alone or in combination with surgery. At the same time,
improvements in the knowledge of liver anatomy and liver
function, and development of new surgical techniques allow
surgeons to go further and further in terms of volume resected
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1507-1367/© 2017 Greater Poland Cancer Centre. Published by Elsevier or biliary and vascular reconstruction. But there are still some
limits. In this way, surgery cannot be seen as the only way
but as being part of a large therapeutic coordinated group
including, oncologists, radiologists, gastroenterologists and
radiotherapists. A multidisciplinary approach and adequate
therapeutic strategies are now the keys to treat more  and more
patients in a curative intent.
2.  Progress  in  surgeryThe respect of some rules and recent advances in knowledge
of liver capacities have enabled liver surgeons to treat more
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nd more  patients and to improve short and long term results
fter hepatic resection.
.1.  Liver  anatomy  and  liver  function
ince the description of surgical liver anatomy by Couinaud
0 years ago,1 a great number of different resection pro-
edures have been described and achieved with very good
mmediate results2: non-anatomical resection, segmentec-
omy, bi-segmentectomy, major resection and extended major
esection. However, some rules must be respected: the future
ive remnant (FLR) must have an adequate afferent and
fferent blood supply, and biliary drainage. Furthermore, the
olume of FLR must be sufficient to maintain a liver func-
ion during the postoperative period. In case of normal liver
unction, an FLR of approximately 25–30% is considered to be
ufficient to maintain liver function after resection.3 But for
atients with hepatic dysfunction (cirrhosis, severe obstruc-
ive jaundice) or earlier liver injury (chemotherapy), a higher
LR of approximately 40% is recommended.4 A good and sim-
le method to estimate resectability is to estimate FLR to a
ody weight ratio which should be greater than 0.5.5 More
ecently, 99mTc-Mebrofenin hepatobiliary Scintigraphy has
een used with success to measure FLR function.6
.2.  Liver  regeneration
f a human or an animal can survive to a 70% ablation of
he liver, this is due to the unique and remarkable capac-
ty of regeneration. In a few weeks, the volume of FLR is
estored. When liver hypertrophy is required preoperatively
portal embolization of a hemi-liver), it has been shown that
he FLR increases from 10 to 46% after a period ranging from
 to 8 weeks.7 But in some cases of underlying pathology (cir-
hosis) or early hepatic toxicity (alcohol abuse, viral infection,
hemotherapy), the capacity of liver regeneration is decreased.
his must be taken into account to stop toxic agents, to plan
he time of operation and the extent of the procedure.
.3.  “Secondary  resectability”  concept
n a significant number of cases, whatever the pathology, a
iver tumour can be considered as unresectable at the time of
iagnosis. The best example is given by colorectal liver metas-
asis. Using the multidisciplinary approach, we  can stretch the
imits of resectability. Thus, when the FLR is too small, we can
nduce hypertrophy by portal vein embolization or portal vein
igation or a combination of portal vein ligation and parenchy-
al  transection.8 When the tumour volume is too important,
ome inductive chemotherapy regiments can induce a sec-
ndary resectability in more  than half of cases.9 When the
isease is bilobar, the concept of two-stage hepatectomy can
e used.10
.4.  Technical  aspectshe main risk factors of postoperative morbidity and mortal-
ty are well known: preservation of blood supply and biliary
rainage, limited per-operative and postoperative blood
oss and sufficient liver volume remnant. Several differenttherapy 2 2 ( 2 0 1 7 ) 176–180 177
technical improvements in recent years allow us to achieve
these main objectives.
2.4.1.  Pre-operative  liver  hypertrophy
If the FLR appears to be too small after operation, it is pos-
sible to induce hypertrophy of the FLR by embolization or
ligation of the portal vein of the contralateral hemi-liver.7
This practice is widely used and has given excellent results
with low morbidity. In some situations, hypertrophy must be
obtained very quickly; a recent procedure which combines
portal vein ligation and parenchymal transection induces sig-
nificant hypertrophy in one week. Two surgical procedures
are requested but in that case morbidity and postoperative
mortality are increased.8
2.4.2.  Vascular  clamping
Even if the procedure of vascular clamping is controversial,
most of the surgical teams around the world use this manoeu-
vre. There are several different techniques from occlusion
of afferent blood supply of one segment to total vascular
exclusion. The most popular and widely used is the “Pringle
manoeuvre”.11 The effect on blood loss is significant and side
effects are low.
2.4.3.  Central  venous  pressure
Management of a low central venous pressure is of tremen-
dous importance and limits blood loss during parenchymal
transection.12
2.5.  Hanging  manoeuvre
It has been understood recently that implementing the liver
transection in anatomical position for major hepatectomy
is very useful, particularly in the case of big lesions. This
represents the concept of anterior approach and hanging
manoeuvre.13
2.6.  Vascular  and  biliary  reconstruction
Some very specialized teams, particularly in Asia, have
published good results after vascular reconstruction of
hepatic arteries, hepatic veins and microscopic biliary
reconstructions.14
2.7.  Raw  surface  management
Hemostasis and biliostasis of the liver raw surface after hepa-
tectomy are essential. Recently, a great number of new devices
such as glue, hemostatic compress, coagulation process have
become available.15
3.  Limits  in  liver  surgery
In different situations, surgery cannot be applied:
Some patients, for extra hepatic reasons, are not suitable
for surgery: the presence of underlying disease such as cirrho-
sis; planned resection would leave in place less than 30% of
liver volume; planned resection would compromise afferent
blood supply of the two hemi-livers or compromise afferent
blood supply on one side and efferent venous drainage on the
d rad178  reports of practical oncology an
other side; biliary drainage of the future liver remnant would
be compromised, too.
In these situations, we need other treatments and a multi-
disciplinary approach.
4.  Multidisciplinary  approach:  the  way  to
push  back  and  stretch  the  limits
When surgery alone is unable to be conducted to “in sano”
resection (R0), combination of different treatments could
be a good option either in the same procedure or in two
postponed procedures. The use in the same procedure of
resection surgery and ablative therapy as radiofrequency is
very common.16 Thus, radio frequency can treat with cura-
tive intent lesions of no more  than 3 or 4 cm,  deep in the
parenchyma and not too close to vascular or biliary struc-
tures. Other types of ablative therapy, such as “microwave”
or “electroporation”, can treat bigger lesions closer to vascu-
lar or biliary structures.17 When surgery cannot be applied in a
patient, other combined treatments have been described: for
example in CHC not suitable for surgery, it is possible to com-
bine chemo embolization for downstaging and radiofrequency
in a curative intent.18
In the next future, one can imagine a place for radiotherapy
in this multidisciplinary approach.
5.  Place  of  stereotactic  radiotherapy
Until now, external beam radiotherapy has had a very limited
place in the treatment of liver cancers. The risk of hepatic tox-
icity has been considered as very high with “radiation-induced
liver disease” represented by hepatitis, fibrosis, cirrhosis and
lethal hepatic insufficiency. This risk has been observed with
a total dose delivered of 30 greys.19
However, it is well known that radiotherapy can induce a
very good local control of liver cancer nearly 90% at 1 or 2
years.20–22
Technical progress in radiotherapy has recently improved
the benefit-risk ratio by optimization of target volumes, pro-
tection of normal liver and best management of respiratory
moves (gating).19
Stereotactic Body Radiation Therapy (SBRT) has the advan-
tage to deliver high doses of radiotherapy to confined areas
while sparing toxicity to surrounding structures of liver
parenchyma.
Thus, with good efficacy and low toxicity, indications might
be extended greatly.
From a surgeon’s point of view, liver SBRT could be indi-
cated in 3 different situations:
(1) In a palliative intent for a local control of some lesions
in patients who  are not considered for surgery or
ablative therapy as some types of intra hepatic cholan-
giocarcinoma, hepatocellular carcinoma or colorectal liver
metastasis.(2) In a multidisciplinary approach, liver SBRT could be used
in combined treatments as it is already done for surgery
and ablative therapy, provided that radiotherapy and other
treatments, such as surgery, cannot be delivered in theiotherapy 2 2 ( 2 0 1 7 ) 176–180
same procedure with the exception of some very special-
ized centres.
(3) In a curative intent as neoadjuvant therapy combined with
chemotherapy. This is already used in some centres for
treatment of selected patients with hilar cholangiocarci-
noma combined with surgery or liver transplantation
6.  Indications  of  SBRT  according  to  disease
6.1.  Hepatocellular  carcinoma  on  cirrhosis  (CHC)
CHC represents a large field of development for radiation ther-
apy. CHC represents 1,000,000 new cases per year worldwide.
Fewer than 30% of patients are eligible for currently avail-
able curative treatments, namely liver transplant, surgical
resection and radiofrequency ablation (RFA) as a result of dis-
ease stage, portal hypertension, poor liver function or limited
resources in the case of transplantation. Radiation represents
an efficient ablative therapy and is an alternative to the exist-
ing options. Foreseeable roles for radiotherapy could be:
(1) Difficult location, e.g. subcapsular location, or tumour
located near the vascular structures or biliary system not
accessible to classic ablative techniques.23
(2) Size larger than 5 cm in which the risk of local failure for
ablative techniques is high.24
(3) Evidence of tumour vascular thrombus in association with
Sorafenib.
(4) Adjuvant treatment after trans-arterial chemoemboliza-
tion (TACE) in the same way that we use RFA after TACE.25
(5) Bridge to liver transplantation for patients who are above
the Milan criteria. For these patients, it has been recently
demonstrated that successful “downstaging” could be a
good prognosis factor.26
6.2.  Intrahepatic  (IHCC)  and  hilar  cholangiocarcinoma
(HCC)
IHCC is a rare tumour with a frequent lymphatic exten-
sion, frequent peritoneal spread and large tumours at the
time of diagnosis. More than 30% are considered irresectable
after morphological evaluation. Furthermore, chemotherapy
regimens, such as the association gembcitabine-oxaliplatine
(Gemox), have poor results. SRBT has recently shown encour-
aging results in terms of local control19 with survival rate
without progression of 70% and 35% at 1 and 2 years.
HCC represents a different disease. If peritoneal spread and
node involvement are frequent, the specific problem is related
to the anatomical situation of the hilum, the frequent vascular
encasement (hepatic artery and portal vein) and the tumour
progression along the wall of the biliary tree. If there is a
local vascular encasement or a bilateral distal biliary exten-
sion without peritoneal and node extension, it is still possible
to have a curative intent. In this case, after an explorative
laparotomy or laparoscopy, which confirm the situation, liver
transplantation after neoadjuvant chemo radiotherapy can
be undertaken. Several centres have published encouraging
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A very similar protocol has been recently published in the
ase of IHCC.28
.3.  Colorectal  liver  metastasis
f resection of colorectal liver metastases is still the gold
tandard, a high rate of patients are not eligible for surgery
ecause of unfavourable tumour factors, difficult location of
esions or poor general condition. Until now, among the other
ocal treatment techniques, RFA is the most widely used. How-
ver, RFA is limited to lesions smaller than 3 cm,  not too close
o major blood vessels or main biliary tree or gallbladder, not
oo close to the diaphragm or the heart and not subcapsular.
n these situations, clearly, SBRT can play a role. Recent study
as demonstrated a 2-year local control of 74% with SBRT.29,30
BRT is becoming a real alternative to RFA.
Furthermore, one can imagine that it will be possible to
ombine surgery with SRBT for bilobar lesions not suitable for
urgery alone or surgery combined with RFA.
Finally, it has been hypothesized that the combination of
adiotherapy and angiogenesis inhibitors may have a syner-
istic effect offering a new therapeutic prospect.31
.4.  Other  tumours
ndications of surgery and SBRT in other primary or secondary
iver tumours are not standardized. Decision must be taken in
 “case by case” discussion during a multidisciplinary meeting.
.  Conclusion
here is no longer any doubt that radiotherapy and partic-
larly SBRT will play a more  and more  important part in
he treatment of liver cancer. In the same way as the use of
adio frequency, the future could combine SBRT and surgery.
iver surgeons are strong supporters of frequent and regular
ultidisciplinary meetings. In each meeting, several patients
iscussed should be potentially eligible for SBRT but radio-
herapists are not commonly present during a “liver cancer
eeting”. If we  wish a quick development of radiotherapy in
ur therapeutic range to face liver cancer, systematic pres-
nce of radiotherapists during these meetings might be a real
rogress.
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